Latest research on Humira

Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.

Humira side effects

TNF blockers, specifically Humira and Remicade, reportedly increase the risk of cancer and serious infections3. [source, 2009]
Interestingly, the HC signal peptide 7 (H7) resulted in significantly increased secretion for Avastin, Remicade, Rituxan and Humira. [source, 2015]
In particular, etanercept induced mainly increases of NK cells while Humira induced mainly B cell increments. [source, 2014]
Adalimumab has a rapid onset of action and sustained efficacy with long-term treatment and is well-tolerated, with few patients discontinuing treatment because of adverse events (Humira PI 2005). [source, 2007]
(2) infliximab; Remicade, Centocor Inc. and (3) adalimumab; Humira, Abbott Laboratories Inc. (both TNF-α monoclonal antibodies) and one that targets IL-1 (4) anakinra; Kineret, Amgen Inc. A reason why this problem is arising for the above three strong TNF-α inhibitors may be because TNF-α has a dual nature. [source, 2005]